Literature DB >> 31518897

YAP Promotes VEGFA Expression and Tumor Angiogenesis Though Gli2 in Human Renal Cell Carcinoma.

Shan Xu1, Haibao Zhang1, Yue Chong1, Bing Guan1, Peng Guo2.   

Abstract

BACKGROUND: High vascularization is a major characteristic of renal cell carcinoma (RCC). Thus, exploration of molecules promoting the tumor vascularization in RCC is urgent. Yes-associated Protein (YAP) is an oncogene in many cancer types, and high YAP expression was correlated with worse overall survival of RCC patients according to The Cancer Genome Atlas (TCGA) database. However, whether YAP promotes tumor angiogenesis of RCC is still unknown.
METHODS: Western blotting assay, real-time Quantitive PCR analysis, and ELISA assay were used to detect the related gene expression. The function of YAP on tumor angiogenesis was investigated by HUVEC recruitment, tube formation, and rabbit cornea assay. The clinical relevance of several genes was analyzed in a public database.
RESULTS: knockdown of YAP decreased RCC cell-inducing HUVEC recruitment and tube formation. Moreover, tumor angiogenesis ability of 786-O cells was crippled by YAP knockdown in vivo. In addition, the expression of Vascular endothelial growth factors A (VEGFA) was positively correlated with YAP expression in RCC tumor tissues, and YAP promoted expression and secretion of VEGFA in RCC cells. Mechanistically, GLI family zinc finger 2 (Gli2) knockdown in RCC cells reduced both basic and YAP-induced VEGFA expression, HUVECs recruitment, and tube formation, indicating that Gli2 is necessary for YAP to promote expression of VEGFA.
CONCLUSION: Taken together, our results demonstrate that YAP/Gli2 promotes VEGFA expression and tumor angiogenesis in RCC cells, which could provide novel therapeutic targets in RCC treatment.
Copyright © 2019 IMSS. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Angiogenesis; Gli2; RCC; VEGFA; YAP

Mesh:

Substances:

Year:  2019        PMID: 31518897     DOI: 10.1016/j.arcmed.2019.08.010

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  7 in total

Review 1.  The Hippo pathway: an emerging role in urologic cancers.

Authors:  Bekir Cinar; Esma Alp; Marwah Al-Mathkour; Ava Boston; Abdulrahman Dwead; Kezhan Khazaw; Alexis Gregory
Journal:  Am J Clin Exp Urol       Date:  2021-08-25

2.  Bioinformatic analysis reveals MIR502 as a potential tumour suppressor in ovarian cancer.

Authors:  Yan Li; Qi Wang; Ning Ning; Fanglan Tang; Yan Wang
Journal:  J Ovarian Res       Date:  2020-07-13       Impact factor: 4.234

3.  SH3BGRL2 inhibits growth and metastasis in clear cell renal cell carcinoma via activating hippo/TEAD1-Twist1 pathway.

Authors:  Lei Yin; Wenjia Li; Aiming Xu; Heng Shi; Keyi Wang; Huan Yang; Ronghao Wang; Bo Peng
Journal:  EBioMedicine       Date:  2020-01-06       Impact factor: 8.143

4.  Vasopressin Receptor Type-2 Mediated Signaling in Renal Cell Carcinoma Stimulates Stromal Fibroblast Activation.

Authors:  Abeda Jamadar; Nidhi Dwivedi; Sijo Mathew; James P Calvet; Sufi M Thomas; Reena Rao
Journal:  Int J Mol Sci       Date:  2022-07-09       Impact factor: 6.208

5.  Systematic Analysis of CXC Chemokine-Vascular Endothelial Growth Factor A Network in Colonic Adenocarcinoma from the Perspective of Angiogenesis.

Authors:  Yongli Situ; Xiaoyong Lu; Yongshi Cui; Qinying Xu; Li Deng; Hao Lin; Zheng Shao; Jv Chen
Journal:  Biomed Res Int       Date:  2022-10-04       Impact factor: 3.246

Review 6.  MicroRNAs Regulating Hippo-YAP Signaling in Liver Cancer.

Authors:  Na-Hyun Lee; So Jung Kim; Jeongeun Hyun
Journal:  Biomedicines       Date:  2021-03-30

Review 7.  Hippo Pathway in Regulating Drug Resistance of Glioblastoma.

Authors:  Giacomo Casati; Laura Giunti; Anna Lisa Iorio; Arianna Marturano; Luisa Galli; Iacopo Sardi
Journal:  Int J Mol Sci       Date:  2021-12-14       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.